FindTrial
Sign In

The impact of therapeutic drug monitoring of carbapenems on clinical outcome in critically ill patients: A prospective, multicenter, randomized controlled study

The impact of therapeutic drug monitoring of carbapenems on clinical outcome in critically ill patients: A prospective, multicenter, randomized controlled study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070424
Enrollment
Unknown
Registered
2023-04-11
Start date
2023-04-07
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

TDM group:Pharmacist adjusts dosage based on TDM
Control group:N/A

Sponsors

Changxing People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years, no gender limit. 2. The clinician diagnosed severe infection or met the diagnostic criteria for sepsis 3.0. 3. The target time for treatment should be at least 2 days. 4. Written informed consent has been obtained from the patient or his or her legally authorized representative.

Exclusion criteria

Exclusion criteria: 1. Pregnant patients. 2. Refused to enroll patients. 3. Pediatric patients. 4. Patients without access to study blood samples.

Design outcomes

Primary

MeasureTime frame
ICU stay time;—

Secondary

MeasureTime frame
28 day mortality;Sequential Organ Failure Score (SOFA);Cost benefit analysis of health economy;Days of use of carbapenems;Use of other antibacterial drugs;—

Countries

China

Contacts

Public ContactLin Bin

Changxing People's Hospital

lb_wzmc@126.com+86 572 626 7652

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026